We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0NLV market cap is 242.99M. The company's latest EPS is EUR -0.1057 and P/E is -40.68.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 20.25M | 20.07M | 28.42M | 68.94M | 77.06M |
| Operating Income | 3.28M | 2.38M | -3.1M | -25.99M | -1.85M |
| Net Income | 1.35M | 1.51M | -3.67M | -27.09M | -1.87M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 61.1M | 58.46M | 177.95M | 151.51M | 158.36M |
| Total Liabilities | 30.83M | 28.93M | 136M | 135.66M | 135.58M |
| Total Equity | 30.27M | 29.54M | 41.94M | 15.85M | 22.78M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 6.32M | 3.98M | 2.73M | -4.49M | 9.15M |
| Investing | -1.39M | -252k | 24.87M | -5.81M | -3.57M |
| Financing | -2.79M | -2.43M | -4.7M | -6.27M | -5.09M |
| Market Cap | 242.99M |
| Price to Earnings Ratio | -40.68 |
| Price to Sales Ratio | 0.98 |
| Price to Cash Ratio | 4.36 |
| Price to Book Ratio | 3.33 |
| Dividend Yield | - |
| Shares Outstanding | 17.64M |
| Average Volume (1 week) | 458 |
| Average Volume (1 Month) | 109 |
| 52 Week Change | 0.00% |
| 52 Week High | 13.775 |
| 52 Week Low | 13.775 |
| Spread (Intraday) | 0.65 (4.61%) |
| Company Name | Vita 34 Ag |
| Address |
deutscher platz 5a leipzig 04103 |
| Website | https://www.vita34.de |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
